Clinical Trial Finder

Inclusion Criteria:

Criteria for all groups:

• - Adults ≥ 18 years.

• - Dated and signed inform consent * - * : written informed consent of relative (trusted person, close family) in case of emergency procedure, by default emergency inclusion notified in medical file and pursuance consent sought.

• - Affiliation with a social security scheme.

Criteria for control group:

• - Age-matched healthy donors.

Criteria for chronic myeloid malignancies:

• - A diagnosis of low or high-risk myelodysplastic syndromes according to the WHO 2016 classification.

• - A diagnosis of dysplastic or proliferative chronic myelomonocytic leukemia according to WHO 2016.

Criteria for COVID-19 patients:

• - Patients with a recent diagnosis (<7 days since first symptoms) of moderate or severe COVID-19.

Exclusion Criteria:

• - Pregnant women.

• - Minor patient or major under protection.

• - Patients with COVID-19 infection and active cancer or a history of cancer within the last 6 months.

- Patients with COVID-19 and severe comorbidities including cardiovascular or respiratory diseases, unbalanced diabetes, obesity (IMC >29) - Patient on AME (state medical aid)

Emergency myelopoiesis in response to SARS-CoV-2 infection produce immunosuppressive myeloid cells with accumulation of immature granulocytes and loss of non-classical monocytes. Excessive release of calprotectin, the dimer of S100A8/A9 alarmins, by immature granulocytes and activated monocytes reflects this situation. A role of calprotectin has been previously described in the initiation and progression of chronic hematological malignancies such as myelodysplastic syndromes. To provide a rationale for the targeting of alarmin-driven signaling pathways and limit the pathogenic inflammatory response to SARS-CoV-2 infection, the role of calprotectin in the production of immunosuppressive cells from the bone marrow hematopoietic stem and progenitors cells needs to be investigated in patients with severe COVID-19 in comparison with patients with chronic myeloid malignancies (such as chronic myelomonocytic leukemia and myelodysplastic syndromes) and with age-mached healthy controls. A comprehensive and integrated multiomics approach will be used to decipher the features of immunosuppressive cells and identify therapeutic targets in deregulated pathways.

Arms

Experimental: COVID-19 patients (group 1)

Patients with a recent diagnosis (<7 days since first symptoms) of moderate or severe COVID-19

Experimental: Chronic myeloid malignancies (group 2)

Adults with chronic myeloid malignancies including myelodysplastic syndromes with low risk MDS ; high risk MDS according to IPSS-R or with dysplastic or proliferative chronic myelomonocytic leukemia according to WHO2016

Other: Control group (group 3)

Age-matched healthy donors

Interventions

Biological: - Blood samples

blood